AF 130

Drug Profile

AF 130

Alternative Names: AF-130

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Roche
  • Developer Afferent Pharmaceuticals
  • Class Analgesics; Antihypertensives; Heart failure therapies; Small molecules
  • Mechanism of Action Purinergic P2X3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hypertension; Migraine

Most Recent Events

  • 18 May 2016 Afferent Pharmaceuticals completes a phase I trial in healthy volunteers in USA (NCT02652936)
  • 18 May 2016 Afferent Pharmaceuticals plans a phase II trial for Hypertension in USA
  • 08 Dec 2015 Phase-I clinical trials in Hypertension in United Kingdom (PO) (NCT02652936)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top